What Aditxt Therapeutics does

Aditxt Therapeutics (NASDAQ: ADTX) is a publicly traded biotechnology holding company founded in 2017 and headquartered in Mountain View, California, that operates as a social innovation platform acquiring and accelerating health technology companies in immune health. The company pursues a Discovery, Development, and Deployment model, building a portfolio of four primary subsidiaries: Adimune (autoimmune disease therapeutics, lead asset ADI-100 — an apoptotic DNA immunotherapy for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome); Pearsanta (early cancer detection via proprietary adductomics); Adivue (neurological diagnostics based on EEG brain monitoring assets acquired from Brain Scientific in January 2024); and Ignite Proteomics (precision oncology, acquired March 2026 for $36 million in Series A-2 Convertible Preferred Stock). Subsidiaries operate semi-independently, with Aditxt providing corporate strategy, capital allocation, and M&A execution rather than integrated R&D.

The product portfolio is anchored by nucleic acid and protein-based technologies. ADI-100 consists of CpG-hyper-methylated DNA plasmids encoding BAX and autoantigen GAD65, designed to restore antigen-specific immune tolerance in autoimmunity rather than broadly suppress the immune system; it is currently in preclinical/IND-enabling stage with planned clinical trials at Mayo Clinic (Stiff Person Syndrome) and German research institutions (Type 1 Diabetes and Psoriasis). Ignite Proteomics operates the only commercial-stage asset — a CLIA-certified laboratory performing functional proteomics testing via Reverse Phase Protein Array (RPPA), reimbursed by Medicare at approximately $2,200 per test for cancer therapy selection, with peer-reviewed clinical validation published in npj Precision Oncology through a Dana-Farber Cancer Institute collaboration demonstrating predictive value for trastuzumab deruxtecan (Enhertu) response in HER2-negative patients. Go-to-market is primarily B2B enterprise sales to healthcare providers and oncologists, with revenue generated through usage-based diagnostic testing fees.

Aditxt has faced significant execution and financial challenges since 2023. Market capitalization collapsed to approximately $450,000 by April 2026, with trailing twelve-month EBITDA of negative $19.3 million. Capital has been raised through multiple small private placements — frequently with distressed terms, including a 20% original issue discount on April 2026 senior unsecured notes at 10% annual interest. A planned $100 million acquisition of Evofem Biosciences was rejected by Evofem shareholders in March 2025. Co-founder Amro Albanna resigned as Chairman and CEO in April 2026 and was succeeded by Jeffrey Busch as interim CEO; Busch concurrently serves as CEO of Ignite Proteomics. Ignite is being spun off via SPAC merger at a $150 million implied equity valuation (announced June 2026), which would create an independent NYSE-listed entity separate from the parent Nasdaq-listed company.

Name

Aditxt Therapeutics

Legal name

Aditxt, Inc.

Website

https://aditxt.com

Company type

Public

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Aditxt Therapeutics is a publicly traded biotech holding company (NASDAQ: ADTX) that acquires and accelerates health technology subsidiaries across autoimmunity (Adimune), early cancer detection (Pearsanta), neurological diagnostics (Adivue), and precision oncology (Ignite Proteomics), serving patients and healthcare providers through its Discover-Develop-Deploy platform model.

Ownership category

akta.pro rank

Product category

Biotechnology

NAICS

Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Proteomics & Biomarker Analytical Testing (HLAGADAG)

akta.pro secondary industries

Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays (HLAAALAN), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)

Keywords

• Precision oncology diagnostics
• Functional proteomics testing
• Immune tolerance therapeutics
• Early cancer detection
• Biotechnology platform

Headquarters

HQ city

Loma Linda

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Precision Oncology Testing: Ignite Proteomics operates CLIA-certified laboratory offering functional proteomics testing with Medicare reimbursement of approximately $2,200 per test. Revenue generated from diagnostic testing services for cancer therapy selection, including targeted therapies and antibody drug conjugates.
2. Women's Health (via Evofem - Proposed): Originally planned to acquire Evofem Biosciences for approximately $100 million, which would have added FDA-approved hormone-free contraceptive gel Phexxi® to the portfolio. Deal was not completed as Evofem shareholders did not approve the merger.
3. Neurological Diagnostics: Acquired EEG brain monitoring assets from Brain Scientific for expansion into neurological diagnostics market.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Aditxt Therapeutics is a biotechnology company that operates as a social innovation platform acquiring and accelerating health technology companies across immune health. Through its wholly owned subsidiaries, it offers functional proteomics-based precision oncology diagnostic testing via CLIA-certified laboratory (Ignite Proteomics), antigen-specific apoptotic DNA immunotherapy for autoimmune diseases such as Type 1 Diabetes (Adimune/ADI-100), adductomics-based early cancer detection screening (Pearsanta), and neurological diagnostics (Adivue).

Product overview

Aditxt operates as a social innovation platform that acquires and develops health technology companies. The portfolio includes Adimune (autoimmunity, restoring immune tolerance), Pearsanta (early cancer detection via adductomics), and Adivue (neurological diagnostics). Through the acquisition of Ignite Proteomics, the company added precision oncology capabilities using functional proteomics for therapy selection. ADI-100 is the company's lead immunotherapeutic product. Planned expansion includes Evofem for reproductive health. The model follows a Discover, Develop, and Deploy approach to accelerate promising health innovations.

Differentiator

Problem solved

Functional benefit

Brands

• Adimune: Developing ADI-100 for autoimmunity treatment, focused on restoring immune tolerance rather than suppressing the immune system. Programs include Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome.
• Pearsanta
• Adivue
• Ignite Proteomics

Products and services

• Adimune A wholly owned subsidiary focused on developing a transformative approach to autoimmunity by restoring immune tolerance rather than suppressing the immune system. Targets Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome with its lead immunotherapeutic ADI-100.
• Pearsanta A wholly owned subsidiary advancing early cancer detection through precision diagnostics, developing adductomics-based screening to monitor early signs of increased cancer risk and enable pre-cancer detection.
• Adivue A wholly owned subsidiary advancing innovative diagnostic solutions for neurodegenerative and neuroinflammatory conditions through EEG brain monitoring.
• Ignite Proteomics Functional Proteomics Testing A CLIA-certified laboratory offering functional proteomics testing using Reverse Phase Protein Array (RPPA) platform to optimize cancer therapy selection for oncologists and healthcare providers. Medicare reimbursement at approximately $2,200 per test. Identifies tumor responses such as TOPO1 expression in HER2-negative patients that standard genomic testing may miss.
• ADI-100 (Apoptotic DNA Immunotherapy) An antigen-specific apoptotic DNA immunotherapeutic designed to suppress autoimmune conditions including Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome. Consists of DNA plasmids encoding apoptosis-inducing BAX and autoantigen GAD65, with CpG hyper-methylated to avoid inflammatory signaling. Demonstrated 80% suppression of diabetes incidence in NOD mouse models.

Quantifiable outcome

• 80% suppression of diabetes incidence in NOD mouse models with ADi-100 treatment
• +2 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core.

• Dana-Farber Cancer InstitutecoreStrategic or Co-development Partner · 20 April 2026Led peer-reviewed study published in npj Precision Oncology demonstrating predictive value of Ignite Proteomics' RPPA platform for patient outcomes in metastatic breast cancer patients treated with trastuzumab deruxtecan (Enhertu). The study found Ignite's platform was the only commercially available multiplex assay evaluated and identified TOPO1 expression in HER2-negative patients.
• Ignite Proteomics LLCcoreOthers · 13 March 2026Aditxt acquired Ignite Proteomics, a commercial-stage precision oncology company focused on optimizing cancer therapy selection through functional proteomics. Operates CLIA-certified laboratory with Medicare reimbursement of approximately $2,200 per test. Transaction valued at $36 million in Series A-2 Convertible Preferred Stock.
• Pearsanta (Subsidiary)coreOthers · 24 March 2025Pearsanta, a wholly owned subsidiary, completed acquisition of proprietary adductomics technology for developing and advancing early cancer detection platform toward clinical and commercial applications for monitoring early signs of increased cancer risk.
• German Research Institutions / Mayo CliniccoreStrategic or Co-development Partner · 6 March 2025Adimune planning clinical trials: Type 1 Diabetes and Psoriasis trials in Germany, and Stiff Person Syndrome trials at Mayo Clinic in the U.S. Adimune to ship drug substances for final drug product formulation of ADI-100.

Scale indicators10 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• NanoString Technologies (now Bruker Spatial Biology): NanoString pioneered protein and gene-expression multiplex profiling on arrays, overlapping with Ignite Proteomics' Reverse Phase Protein Array (RPPA) approach to high-throughput, functional proteomic characterization of tumor samples used to inform therapy selection.
• Caris Life Sciences: Caris provides multi-omic molecular profiling (DNA, RNA, protein) for therapy selection in metastatic cancer, directly comparable to Ignite's functional proteomics service aimed at identifying ADC responders beyond standard genomic testing.
• Personalis: Personalis offers tumor molecular profiling including proteomics-informed assays for therapy selection in solid tumors; it is comparable to Ignite Proteomics in providing deep molecular characterization services ordered by oncologists to guide targeted treatment.
• Myriad Genetics: Myriad is an established specialty molecular diagnostics company focused on oncology and hereditary disease testing; it shares Ignite's positioning as a specialized lab offering payer-reimbursed clinical assays for therapy-relevant biomarkers.
• Guardant Health: Guardant is a leading liquid-biopsy oncology diagnostics company selling comprehensive tumor profiling tests to oncologists, directly comparable to Ignite in delivering CLIA-certified, Medicare-reimbursed molecular tests that inform targeted therapy selection.
• Natera: Natera develops and commercializes specialty molecular diagnostics, including tumor-informed ctDNA assays for oncology therapy monitoring; it overlaps with Ignite's positioning as a specialty CLIA lab selling reimbursed molecular tests to cancer treatment centers.
• Prometheus Laboratories (a Nestlé Health Science company): Prometheus is a specialty diagnostics company focused on autoimmune and gastroenterology testing using proprietary biomarkers, directly comparable to Adimune's focus on autoimmune disease biology in Type 1 Diabetes, IBD-adjacent indications, and immune tolerance.

Broad incumbents

• Foundation Medicine (Roche): Foundation Medicine, owned by Roche, is the established leader in comprehensive genomic profiling (CGP) for solid tumors, sitting in the same oncologist-ordered specialty diagnostics market where Ignite competes for ADC and targeted-therapy selection share.
• Exact Sciences: Exact Sciences is a publicly traded diagnostics leader in cancer screening (e.g., Cologuard) and therapy-selection testing; relevant to both Ignite (specialty oncology diagnostics) and Pearsanta (early cancer detection via adductomics) at Aditxt.
• Roivant Sciences: Roivant operates a "Vant" platform model that acquires, develops, and commercializes multiple therapeutic programs in parallel — structurally analogous to Aditxt's Discover-Develop-Deploy platform that holds Adimune, Pearsanta, Adivue and Ignite under a single listed parent.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights6 records

Customer concentration

• Xtwitter.com/aditxt
• YouTubeyoutube.com/@aditxtinc.4150
• Facebookfacebook.com/aditxtplatform
• LinkedInlinkedin.com/company/aditxt

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries5 records

Funding overview

Funding rounds9 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aditxt Therapeutics